IL6R and rheumatoid arthritis: This strategy has been integrated into the treatment of rheumatoid arthritis with high success as well: notably Tocilizumab (Target: IL-6R), Adalimumab (Target: TNFα) and Goliumab (Target: TNFα) are approved and highly successful therapeutics as mono- or combination therapy with DMARDs (222–227).